Patient, disease, donor, and transplantation characteristics of the 212 enrolled patients
| Characteristics . | Median (range) N (%) . |
|---|---|
| Patient | |
| Age, y | 31 (3.3-55.8) |
| Weight, kg | 64 (13.6-100) |
| Female | 82 (38.7%) |
| Positive CMV serology | 139 (65.6%) |
| Underlying diagnosis | |
| Chronic leukemia* | 56 (26.4%) |
| Acute leukemia† | 87 (41.0%) |
| Other malignancies‡ | 33 (15.6%) |
| Non-malignancies1-153 | 36 (17.0%) |
| Disease stage (for malignancies) | |
| Advanced1-155 | 27 (12.7%) |
| Donor | |
| Age, y | 30 (1.2-64.8) |
| Female | 88 (41.5%) |
| Sex match | 96 (45.3%) |
| Donor F recipient M | 61 (28.8%) |
| ABO match | 149 (70.3%) |
| ABO major mismatch | 37 (17.4%) |
| Positive CMV serology | 108 (50.9%) |
| Transplantation | |
| GVH prophylaxis | |
| Cyclosporin + methotrexate | 174 (82.2%) |
| Cyclosporin + methotrexate + other | 23 (10.8%) |
| Cyclosporin ± corticosteroids | 15 (7.1%) |
| Conditioning | |
| Irradiation based | 86 (40.6%) |
| TBI + Cy ± others | 38 |
| TBI + Mel ± others | 42 |
| TAI + low-dose Cy | 6 |
| Chemotherapy based | 126 (59.4%) |
| Bu + Cy | 76 |
| Bu + Cy + VP16 | 24 |
| Cy | 21 |
| Bu + others | 5 |
| Laboratory values | |
| NC, 108/kg | 2.4 (0.28-5.97) |
| CD34, 106/kg | 3.7 (0.07-18.7) |
| CD3, 106/kg, n = 48 | 2.2 (0.3-5.4) |
| NC ≥ 2.4 × 106/kg | 111 (52.4%) |
| CD34 ≥ 3.0 × 106/kg | 142 (67.0%) |
| Use of prophylactic hematopoietic growth factors (until day + 7) | 13 (6.1%) |
| Characteristics . | Median (range) N (%) . |
|---|---|
| Patient | |
| Age, y | 31 (3.3-55.8) |
| Weight, kg | 64 (13.6-100) |
| Female | 82 (38.7%) |
| Positive CMV serology | 139 (65.6%) |
| Underlying diagnosis | |
| Chronic leukemia* | 56 (26.4%) |
| Acute leukemia† | 87 (41.0%) |
| Other malignancies‡ | 33 (15.6%) |
| Non-malignancies1-153 | 36 (17.0%) |
| Disease stage (for malignancies) | |
| Advanced1-155 | 27 (12.7%) |
| Donor | |
| Age, y | 30 (1.2-64.8) |
| Female | 88 (41.5%) |
| Sex match | 96 (45.3%) |
| Donor F recipient M | 61 (28.8%) |
| ABO match | 149 (70.3%) |
| ABO major mismatch | 37 (17.4%) |
| Positive CMV serology | 108 (50.9%) |
| Transplantation | |
| GVH prophylaxis | |
| Cyclosporin + methotrexate | 174 (82.2%) |
| Cyclosporin + methotrexate + other | 23 (10.8%) |
| Cyclosporin ± corticosteroids | 15 (7.1%) |
| Conditioning | |
| Irradiation based | 86 (40.6%) |
| TBI + Cy ± others | 38 |
| TBI + Mel ± others | 42 |
| TAI + low-dose Cy | 6 |
| Chemotherapy based | 126 (59.4%) |
| Bu + Cy | 76 |
| Bu + Cy + VP16 | 24 |
| Cy | 21 |
| Bu + others | 5 |
| Laboratory values | |
| NC, 108/kg | 2.4 (0.28-5.97) |
| CD34, 106/kg | 3.7 (0.07-18.7) |
| CD3, 106/kg, n = 48 | 2.2 (0.3-5.4) |
| NC ≥ 2.4 × 106/kg | 111 (52.4%) |
| CD34 ≥ 3.0 × 106/kg | 142 (67.0%) |
| Use of prophylactic hematopoietic growth factors (until day + 7) | 13 (6.1%) |
CMV indicates cytomegalovirus; GVH, graft-versus-host; TBI, total body irradiation; TAI, thoracoabdominal irradiation; Cy, cyclophosphamide; Mel, melphalan; Bu, busulfan; VP16, etoposide; NC, nucleated cells.
55 chronic myeloid leukemia (CML): 37 in first chronic phase (CP), 5 in second CP, 11 in accelerated phase, and 2 in blastic crisis; 1 chronic lymphocytic leukemia.
45 acute lymphoblastic leukemia (ALL): 27 in first complete remission (CR1), 6 in CR2, 3 in CR3+, and 9 in relapse/refractory (REL) disease; 42 acute myeloblastic leukemia (AML): 31 in CR1, 7 in CR2, and 4 in REL disease.
14 Non-Hodgkin lymphoma (NHL), 12 myelodysplastic syndrome (MDS), 7 other myeloproliferative syndromes.
23 Severe aplastic anemia, 7 Fanconi anemia, 4 paroxysmal nocturnal hemoglobinuria, 1 congenital dyserythropoietic anemia, and 1 Glanzmann thrombasthenia.
Advanced stage: CML in blastic crisis, AML/ALL in relapse or refractory disease, NHL in resistant or untreated relapse, MDS classified as refractory anemia with excess of blast or with excess of blast in transformation and secondary acute leukemia (modified from IBMTR classification).